lonafarnib has been researched along with fluorouracil in 4 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (fluorouracil) | Trials (fluorouracil) | Recent Studies (post-2010) (fluorouracil) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 45,562 | 9,307 | 14,663 |
| Protein | Taxonomy | lonafarnib (IC50) | fluorouracil (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.32 | |
| Thymidylate synthase | Mus musculus (house mouse) | 1.58 | |
| Aromatase | Homo sapiens (human) | 0.63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, AA; Bruzek, LM; Davis, JN; Erlichman, C; Kaufmann, SH | 1 |
| Baum, C; Hollywood, E; Ilson, D; Kelsen, DP; Kemeny, N; O'Reilly, E; Saltz, LB; Sharma, S; Statkevich, P; Zaknoen, S; Zhu, Y | 1 |
| Adjei, AA; Dy, GK | 1 |
| Johnson, WW; Wang, EJ | 1 |
1 review(s) available for lonafarnib and fluorouracil
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
1 trial(s) available for lonafarnib and fluorouracil
| Article | Year |
|---|---|
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
2 other study(ies) available for lonafarnib and fluorouracil
| Article | Year |
|---|---|
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Cycle; Cisplatin; DNA Adducts; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Melphalan; Piperidines; Platinum; Pyridines; Tumor Cells, Cultured | 2001 |
The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cisplatin; Cyclophosphamide; Drug Interactions; Drug Resistance, Multiple; Flow Cytometry; Fluorouracil; Humans; Piperidines; Pyridines | 2003 |